Using existing NHS datasets to determine outcomes of cancer medicines: a feasibility study

Kelly Baillie, Tanja Mueller, Jiafeng Pan, Christine Crearie, Jennifer Laskey, Robert Jones, Marion Bennie

Research output: Contribution to conferencePoster

Abstract

Based on recent clinical trial evidence, updated treatment guidelines in the UK recommend high-intensity statin therapy (atorvastatin 80mg) for secondary prevention of cardiovascular disease. However, with this high statin dose, there are concerns about a potential increase in the incidence of statin-related side effects, which might affect patients’ adherence and, in turn, clinical outcomes. Hence, this study aimed to evaluate the effect of statin intensity on adherence and persistence to therapy.

Conference

Conference34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
CountryCzech Republic
CityPrague
Period22/08/1826/08/18

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Feasibility Studies
Neoplasms
Patient Compliance
Secondary Prevention
Cardiovascular Diseases
Therapeutics
Clinical Trials
Guidelines
Datasets
Incidence

Keywords

  • cancer medicines
  • medicine results

Cite this

Baillie, K., Mueller, T., Pan, J., Crearie, C., Laskey, J., Jones, R., & Bennie, M. (Accepted/In press). Using existing NHS datasets to determine outcomes of cancer medicines: a feasibility study. Poster session presented at 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.
Baillie, Kelly ; Mueller, Tanja ; Pan, Jiafeng ; Crearie, Christine ; Laskey, Jennifer ; Jones, Robert ; Bennie, Marion. / Using existing NHS datasets to determine outcomes of cancer medicines : a feasibility study. Poster session presented at 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.2 p.
@conference{1e872989e5134bf7864f9e2cf30dd447,
title = "Using existing NHS datasets to determine outcomes of cancer medicines: a feasibility study",
abstract = "Based on recent clinical trial evidence, updated treatment guidelines in the UK recommend high-intensity statin therapy (atorvastatin 80mg) for secondary prevention of cardiovascular disease. However, with this high statin dose, there are concerns about a potential increase in the incidence of statin-related side effects, which might affect patients’ adherence and, in turn, clinical outcomes. Hence, this study aimed to evaluate the effect of statin intensity on adherence and persistence to therapy.",
keywords = "cancer medicines, medicine results",
author = "Kelly Baillie and Tanja Mueller and Jiafeng Pan and Christine Crearie and Jennifer Laskey and Robert Jones and Marion Bennie",
year = "2018",
month = "6",
day = "18",
language = "English",
note = "34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management ; Conference date: 22-08-2018 Through 26-08-2018",

}

Baillie, K, Mueller, T, Pan, J, Crearie, C, Laskey, J, Jones, R & Bennie, M 2018, 'Using existing NHS datasets to determine outcomes of cancer medicines: a feasibility study' 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic, 22/08/18 - 26/08/18, .

Using existing NHS datasets to determine outcomes of cancer medicines : a feasibility study. / Baillie, Kelly; Mueller, Tanja; Pan, Jiafeng; Crearie, Christine; Laskey, Jennifer; Jones, Robert; Bennie, Marion.

2018. Poster session presented at 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.

Research output: Contribution to conferencePoster

TY - CONF

T1 - Using existing NHS datasets to determine outcomes of cancer medicines

T2 - a feasibility study

AU - Baillie, Kelly

AU - Mueller, Tanja

AU - Pan, Jiafeng

AU - Crearie, Christine

AU - Laskey, Jennifer

AU - Jones, Robert

AU - Bennie, Marion

PY - 2018/6/18

Y1 - 2018/6/18

N2 - Based on recent clinical trial evidence, updated treatment guidelines in the UK recommend high-intensity statin therapy (atorvastatin 80mg) for secondary prevention of cardiovascular disease. However, with this high statin dose, there are concerns about a potential increase in the incidence of statin-related side effects, which might affect patients’ adherence and, in turn, clinical outcomes. Hence, this study aimed to evaluate the effect of statin intensity on adherence and persistence to therapy.

AB - Based on recent clinical trial evidence, updated treatment guidelines in the UK recommend high-intensity statin therapy (atorvastatin 80mg) for secondary prevention of cardiovascular disease. However, with this high statin dose, there are concerns about a potential increase in the incidence of statin-related side effects, which might affect patients’ adherence and, in turn, clinical outcomes. Hence, this study aimed to evaluate the effect of statin intensity on adherence and persistence to therapy.

KW - cancer medicines

KW - medicine results

UR - https://www.pharmacoepi.org/meetings/34icpe/

M3 - Poster

ER -

Baillie K, Mueller T, Pan J, Crearie C, Laskey J, Jones R et al. Using existing NHS datasets to determine outcomes of cancer medicines: a feasibility study. 2018. Poster session presented at 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management , Prague, Czech Republic.